Original Investigation | Publication Year | First Author | # of weeks to first follow-up encounter, at least 3 months (at 12 weeks) since onset of semaglutide dose | Starting dose semaglutide | HbA1c % reduction at first follow-up encounter | HbA1c % reduction at second follow-up encounter (if applicable) |
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | 2022 | Garvey | 20 | 2.4 mg | 0.53% | 0.55% |
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. | 2022 | Ghusn | n/a | n/a | n/a | n/a |
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial | 2021 | Wadden | n/a | n/a | n/a | n/a |
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial | 2017 | Ahren | 56 | 1.0 mg | 1.60% | n/a |
|
|
|
| Average percent reduction rate of HbA1c | 1.07% |
|